£16 million Series A led by Omega Funds, to advance disease-modifying oral medicines for debilitating chronic neurodegenerative disorders through IND-enabling.
Two heads are better than one, or so the saying goes. And a collaborative or ecosystem approach to innovation can open up new avenues for growth and fresh ways of working, and stands to make organisations more competitive.
Report demonstrates Stevenage Bioscience Catalyst’s key role in delivering the economic benefit from leading edge UK life sciences Stevenage, UK – 9th December 2021. An independent report has been released today by Stevenage Bioscience Catalyst (SBC) that demonstrates its key role in delivering econ.
According to a July 16, 2021, report from Fierce Biotech, GlaxoSmithKline (GSK) announced plans to sell 33 acres of its 92-acre R&D site in Stevenage, UK.
The proposed sale comes at a time of criticism over GSK s historically low investment in R&D. Through the sale, the company will unlock US $554 million in investments from a private sector developer that seeks to build a campus for biotech and other early stage life science companies.
The site already houses the Cell and Gene Therapy Catapult and Stevenage Bioscience Catalyst, Fierce Biotech reports, the latter of which is home to more than 40 companies. Developing 33 acres into a life science campus would significantly increase the number of start-ups that could be based there.